Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015
April 30 2015 - 4:05PM
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company
focused on the discovery, development and commercialization of
recombinant nanoparticle vaccines and adjuvants, today announced it
will report its first quarter 2015 financial and operating results
after the close of U.S. financial markets on Thursday, May 7, 2015.
In addition, management will host a conference call to discuss
the quarterly results and provide an update on corporate
activities.
Conference call details are as
follows: |
Date: |
May 7, 2015 |
Time: |
4:30 pm US Eastern Time |
Dial-in number: |
(877) 212-6076 (Domestic) or (707) 287–9331
(International) |
Via web: |
www.novavax.com, "Investor
Info"/"Events" |
|
|
Conference call replay: |
Dates: |
Starting at 7:30 pm ET on May 7, 2015 until
midnight May 14, 2015 |
Dial-in number: |
(855) 859-2056 (Domestic) or (404) 537-3406
(International) |
Passcode: |
35660022 |
Via web: |
www.novavax.com, "Investor
Info"/"Events" |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company
committed to delivering novel products to prevent a broad range of
infectious diseases. Its recombinant nanoparticles and Matrix-M™
adjuvant technology are the foundation for ground-breaking
innovation that improves global health through safe and effective
vaccines. Additional information about Novavax is available on the
company's website, www.novavax.com.
CONTACT: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024